The microsome product line formulated to deliver different classifications of cytochrome P450 (CYP) enzyme activity, high levels for inhibitions studies (InVitroCYP H-class), moderate levels for metabolic studies (InVitroCYP M-class) and custom activity levels (InVitroCYP C-class), Celsis InVitroCYP now enables researchers to choose a microsome product to optimize their specific study outcomes.
Philip Vorwald, vice president and general manager of Celsis In Vitro Technologies, said: “InVitroCYP is the first product for the ADME-Tox market that delivers microsome products specifically for metabolic or inhibition studies without compromising P450 values, and without the time and cost of custom blending.”